Martin L. Korn, M.D.; Decision and Order, 66406-66407 [2014-26447]
Download as PDF
66406
Federal Register / Vol. 79, No. 216 / Friday, November 7, 2014 / Notices
The publication of this notice opens
a period for public comment on the
proposed Consent Decree. Comments
should be addressed to the Assistant
Attorney General, Environment and
Natural Resources Division, and should
refer to United States et al. v. Hyundai
Motor Company et al. (Civil Action No.
1:14–cv–1837), D.J. Ref. No. 90–5–2–1–
10753. All comments must be submitted
no later than thirty (30) days after the
publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit
comments:
Send them to:
By e-mail ......
pubcomment-ees.enrd@
usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
By mail .........
During the public comment period,
the proposed Consent Decree may be
examined and downloaded at this
Justice Department Web site: https://
www.usdoj.gov/enrd/Consent_
Decrees.html. We will provide a paper
copy of the proposed Consent Decree
upon written request and payment of
reproduction costs. Please mail your
request and payment to: Consent Decree
Library, U.S. DOJ—ENRD, P.O. Box
7611, Washington, DC 20044–7611.
Please enclose a check or money order
for $11.00 (25 cents per page
reproduction cost) payable to the United
States Treasury.
Maureen Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2014–26512 Filed 11–6–14; 8:45 am]
BILLING CODE 4410–15–P
JUSTICE DEPARTMENT
Drug Enforcement Administration
mstockstill on DSK4VPTVN1PROD with NOTICES
Martin L. Korn, M.D.; Decision and
Order
On August 23, 2013, I, the Deputy
Administrator of the Drug Enforcement
Administration, issued an Order to
Show Cause and Immediate Suspension
of Registration (hereinafter, OTSC/ISO
or Order) to Martin L. Korn, M.D.
(hereinafter, Registrant). GX 1, at 1. The
OTSC/ISO proposed the revocation of
Registrant’s DEA Certificate of
Registration, pursuant to which he was
authorized to dispense controlled
substances as a practitioner, based on
allegations that on ‘‘[o]n twelve separate
occasions’’ between February 20 and
VerDate Sep<11>2014
19:12 Nov 06, 2014
Jkt 235001
June 24, 2013, Registrant prescribed
controlled substances including
alprazolam (schedule IV) and Adderall
(schedule II), ‘‘to three law enforcement
officers working in an undercover
capacity . . . without a legitimate
medical purpose and/or outside the
usual course of professional practice.’’
Id. at 1–2 (citing 21 CFR 1306.04(a)).
Based on the above, I further concluded
that Registrant’s ‘‘continued registration
while these proceedings [were] pending
constitutes an imminent danger to the
public health and safety’’ and ordered
that his registration be immediately
suspended. Id. at 3 (citing 21 U.S.C.
§ 824(d)). The OTSC/ISO also notified
Registrant of his right to request a
hearing on the allegations or to submit
a written statement in lieu of a hearing,
the procedures for electing either
option, and the consequence of failing
to elect either option. Id. at 3–4 (citing
21 CFR 1301.43).
On September 5, 2013, a DEA Special
Agent served Registrant with the OTSC/
ISO at the Westchester County District
Attorney’s Office. GX 2. According to
the Government, Registrant has not
requested a hearing on the allegations
nor otherwise responded to the OTSC.
Request for Final Agency Action, at 1.
Based on the Government’s
representation, I find that more than
thirty (30) days have now passed since
the OTSC/ISO was served on Registrant
and that he has neither requested a
hearing nor submitted a written
statement in lieu of a hearing. I therefore
find that Registrant has waived his right
to a hearing or to submit a written
statement in lieu of a hearing. 21 CFR
1301.43(d). I make the following
findings.
Registrant previously held a DEA
Certificate of Registration, pursuant to
which he was authorized to dispense
controlled substances as a practitioner
at registered premises located in
Larchmont, New York. On December 31,
2013, this registration expired. GX 3, at
1. According to the Agency’s
registration records, Registrant has not
filed a renewal application.
Pursuant to the authority granted by
21 U.S.C. § 824(f), DEA seized
approximately 300 dosage units of
various controlled substances which
apparently were in prescription vials,
some of which bore the names of
patients. GX A, at 2. The drugs included
two vials containing 144 and 19 dosage
units of lorazepam .5mg bearing labels
listing the patients as A.K. and C.A.
respectively; a vial containing 16 tablets
of phentermine 37.5mg bearing a label
listing the patient as J.L.; a vial
containing 80 tablets of oxazepam, its
label having been ripped off; a vial
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
containing 13 tablets of temazepam
15mg bearing a label listing the patient
as K.M.; a vial containing 10.5 tablets of
hydrocodone 10/325 bearing a label
listing the patient as A.K.; and vials
containing 11 tablets of Lyrica 50mg and
6 tablets of Lyrica 25mg, neither of
which had a patient name. Id.
On April 10, 2014, DEA’s New York
Field Division wrote to Registrant
noting that following the expiration of
his DEA registration, he no longer had
authority to handle controlled
substances. Id. at 1. The letter further
informed him that under federal law,
the Agency was authorized to dispose of
the drugs 180 days after the date on
which they had been seized. Id.
However, the letter instructed Registrant
that ‘‘[i]n the event you wish to transfer
title to the controlled substances to a
registered successor in interest, you may
notify this office within thirty (30) days
from the date of this letter to make
arrangements for such a transfer. . . .
However, if you fail to notify the office
within thirty days, DEA will dispose of
. . . the controlled . . . substances it
currently holds.’’ Id. According to the
Government, Registrant did not respond
to the letter. See Gov. Suggestion of
Mootness, at 1.
Discussion
While the Government initially filed a
Request for Final Agency Action, it now
suggests that this case is moot because
Registrant has allowed his registration
to expire and ‘‘there is no need to
determine title to the controlled
substances that were seized.’’ Id. at 2. I
agree.
Ordinarily, where a registrant allows
his registration to expire and also fails
to file a renewal application, there is
neither a registration to revoke nor an
application to act upon, thus rendering
the case moot. See, e.g., Ronald J. Riegel,
63 FR 67132 (1998). DEA, however, has
recognized a limited exception to this
rule in cases which commence with the
issuance of an immediate suspension
order because of the collateral
consequences which may attach with
the issuance of such a suspension. See
William R. Lockridge, 71 FR 77791,
77797 (2006). Such ‘‘collateral
consequences’’ may include the loss of
title to any controlled substances that
have been seized pursuant to the
immediate suspension order, see 21
U.S.C. § 824(f), harm to reputation, and
having to report the suspension on
future applications to either this Agency
or a state board. See Lockridge, 71 FR at
77797.
While this case commenced with the
issuance of an immediate suspension
order, I nonetheless conclude it is now
E:\FR\FM\07NON1.SGM
07NON1
66407
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 216 / Friday, November 7, 2014 / Notices
moot. Here, while various controlled
substances were seized, the Government
subsequently provided registrant with
the opportunity to transfer the
controlled substances to a registered
successor in interest. See 21 U.S.C.
§ 824(g). Thus, to the extent the
controlled substances had any market
value—which appears highly unlikely
anyway given that they were in
prescription vials and not sealed
commercial containers—the
Government disclaimed any interest in
them. Registrant’s failure to respond to
the Government’s offer itself constitutes
a waiver of any claim to title to the
drugs. Thus, there is no need to issue a
decision on the merits to adjudicate the
issue of title to the drugs.
To the extent the issuance of the
Immediate Suspension has harmed
Registrant’s reputation and may result
in his having to report this action on
future applications for a DEA
registration or a state license, Registrant
was provided with the opportunity to
request a hearing and challenge the
basis of the Government’s action.
Registrant did not, however, seek to do
so. See Richard C. Quigley, 79 FR 50945,
50947 (2014) (rejecting Government’s
contention that ISO case was not moot
because of potential harm to physician’s
reputation when physician did not
request a hearing).
It is acknowledged that several federal
appeals courts have held that ‘‘the mere
possibility of adverse collateral
consequences is sufficient to preclude a
finding of mootness.’’ In re Surrick, 338
F.3d 224, 230 (3d Cir. 2003) (quoting
Dailey v. Vought Aircraft Co., 141 F.3d
224, 228 (5th Cir. 1998)). But in those
cases, which involved sanctions
imposed by courts on attorneys, the
person who was sanctioned at least
cared enough to litigate. Not so here. So
too, this case stands in contrast to those
cases where the Agency has ruled on the
validity of a suspension order
notwithstanding that a registrant
allowed his/her registration to expire
and failed to file a renewal application.
See Lockridge, 71 FR at 77797 (holding
case not moot where registrant subject
to ISO did not allow registration to
expire until after receiving adverse
recommended decision from ALJ); see
also Nirmal Saran & Nisha Saran, 73 FR
7827, 7835 n.29 (2008) (holding case not
moot where during proceeding,
registrants’ registrations expired but
registrants asserted that they intended to
remain in professional practice and had
attempted to renew their registrations
online but been prevented from doing
so). Accordingly, I conclude that this
case is moot. See Tin T. Win, 78 FR
52802 (2013) (holding ISO proceeding
VerDate Sep<11>2014
19:12 Nov 06, 2014
Jkt 235001
moot where physician, who allowed her
registration to expire, failed to request a
hearing and no controlled substances
had been seized); Robert Charles Ley, 76
FR 20033 (2011) (holding ISO
proceeding moot where physician
eventually waived his right to a hearing
and no controlled substances had been
seized).
compliance with state and local laws,
and reviewed the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed:–
Order
Controlled substance
Pursuant to the authority vested in me
by 21 U.S.C. § 824(a), as well as 28 CFR
0.100(b) and 0.104, I order that the
Order to Show Cause and Immediate
Suspension of Registration issued to
Martin L. Korn, M.D., be, and it hereby
is, dismissed. This Order is effective
immediately.
Dated: October 23, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014–26447 Filed 11–6–14; 8:45 am]
BILLING CODE 4410–09–P
JUSTICE DEPARTMENT
Drug Enforcement Administration
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: Alltech
Associates, Inc.
ACTION:
Notice of registration.
Alltech Associates, Inc.,
applied to be registered as a
manufacturer of certain basic classes of
controlled substances. The DEA grants
Alltech Associates, Inc. registration as a
manufacturer of those controlled
substances.
SUMMARY:
By notice
dated May 2, 2014, and published in the
Federal Register on May 15, 2014, 79
FR 27936, Alltech Associates, Inc., 2051
Waukegan Road, Deerfield, Illinois
60015, applied to be registered as a
manufacturer of certain basic classes of
controlled substances. No comments or
objections were submitted to this notice.
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823(a) and
determined that the registration of
Alltech Associates, Inc., to manufacture
the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. The DEA investigated the
company’s maintenance of effective
controls against diversion by inspecting
and testing the company’s physical
security systems, verified the company’s
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
4-Methylaminorex (cis isomer)
(1590).
Gamma
Hydroxybutyric
Acid
(2010).
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
2C-T-7
(2,5-Dimethoxy-4-(n)propylthiophenethylamine)
(7348).
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
2C-T-2
(2-(4-Ethylthio-2,5dimethoxyphenyl)ethanamine)
(7385).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-N-ethylamphetamine (7404).
3,4-Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
5-Methoxy-N-Ndimethyltryptamine (7431).
Alpha-methyltryptamine (7432) ....
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
N-Ethyl-1-phenylcyclohexylamine
(7455).
1-(1-Phenylcyclohexyl)pyrrolidine
(7458).
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
2C-E
(2-(2,5-Dimethoxy-4ethylphenyl)ethanamine) (7509).
2C-H
(2-(2,5Dimethoxyphenyl)ethanamine)
(7517).
2C-I
(2-(4-lodo-2,5dimethoxyphenyl)ethanamine)
(7518).
E:\FR\FM\07NON1.SGM
07NON1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Agencies
[Federal Register Volume 79, Number 216 (Friday, November 7, 2014)]
[Notices]
[Pages 66406-66407]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-26447]
-----------------------------------------------------------------------
JUSTICE DEPARTMENT
Drug Enforcement Administration
Martin L. Korn, M.D.; Decision and Order
On August 23, 2013, I, the Deputy Administrator of the Drug
Enforcement Administration, issued an Order to Show Cause and Immediate
Suspension of Registration (hereinafter, OTSC/ISO or Order) to Martin
L. Korn, M.D. (hereinafter, Registrant). GX 1, at 1. The OTSC/ISO
proposed the revocation of Registrant's DEA Certificate of
Registration, pursuant to which he was authorized to dispense
controlled substances as a practitioner, based on allegations that on
``[o]n twelve separate occasions'' between February 20 and June 24,
2013, Registrant prescribed controlled substances including alprazolam
(schedule IV) and Adderall (schedule II), ``to three law enforcement
officers working in an undercover capacity . . . without a legitimate
medical purpose and/or outside the usual course of professional
practice.'' Id. at 1-2 (citing 21 CFR 1306.04(a)). Based on the above,
I further concluded that Registrant's ``continued registration while
these proceedings [were] pending constitutes an imminent danger to the
public health and safety'' and ordered that his registration be
immediately suspended. Id. at 3 (citing 21 U.S.C. Sec. 824(d)). The
OTSC/ISO also notified Registrant of his right to request a hearing on
the allegations or to submit a written statement in lieu of a hearing,
the procedures for electing either option, and the consequence of
failing to elect either option. Id. at 3-4 (citing 21 CFR 1301.43).
On September 5, 2013, a DEA Special Agent served Registrant with
the OTSC/ISO at the Westchester County District Attorney's Office. GX
2. According to the Government, Registrant has not requested a hearing
on the allegations nor otherwise responded to the OTSC. Request for
Final Agency Action, at 1. Based on the Government's representation, I
find that more than thirty (30) days have now passed since the OTSC/ISO
was served on Registrant and that he has neither requested a hearing
nor submitted a written statement in lieu of a hearing. I therefore
find that Registrant has waived his right to a hearing or to submit a
written statement in lieu of a hearing. 21 CFR 1301.43(d). I make the
following findings.
Registrant previously held a DEA Certificate of Registration,
pursuant to which he was authorized to dispense controlled substances
as a practitioner at registered premises located in Larchmont, New
York. On December 31, 2013, this registration expired. GX 3, at 1.
According to the Agency's registration records, Registrant has not
filed a renewal application.
Pursuant to the authority granted by 21 U.S.C. Sec. 824(f), DEA
seized approximately 300 dosage units of various controlled substances
which apparently were in prescription vials, some of which bore the
names of patients. GX A, at 2. The drugs included two vials containing
144 and 19 dosage units of lorazepam .5mg bearing labels listing the
patients as A.K. and C.A. respectively; a vial containing 16 tablets of
phentermine 37.5mg bearing a label listing the patient as J.L.; a vial
containing 80 tablets of oxazepam, its label having been ripped off; a
vial containing 13 tablets of temazepam 15mg bearing a label listing
the patient as K.M.; a vial containing 10.5 tablets of hydrocodone 10/
325 bearing a label listing the patient as A.K.; and vials containing
11 tablets of Lyrica 50mg and 6 tablets of Lyrica 25mg, neither of
which had a patient name. Id.
On April 10, 2014, DEA's New York Field Division wrote to
Registrant noting that following the expiration of his DEA
registration, he no longer had authority to handle controlled
substances. Id. at 1. The letter further informed him that under
federal law, the Agency was authorized to dispose of the drugs 180 days
after the date on which they had been seized. Id. However, the letter
instructed Registrant that ``[i]n the event you wish to transfer title
to the controlled substances to a registered successor in interest, you
may notify this office within thirty (30) days from the date of this
letter to make arrangements for such a transfer. . . . However, if you
fail to notify the office within thirty days, DEA will dispose of . . .
the controlled . . . substances it currently holds.'' Id. According to
the Government, Registrant did not respond to the letter. See Gov.
Suggestion of Mootness, at 1.
Discussion
While the Government initially filed a Request for Final Agency
Action, it now suggests that this case is moot because Registrant has
allowed his registration to expire and ``there is no need to determine
title to the controlled substances that were seized.'' Id. at 2. I
agree.
Ordinarily, where a registrant allows his registration to expire
and also fails to file a renewal application, there is neither a
registration to revoke nor an application to act upon, thus rendering
the case moot. See, e.g., Ronald J. Riegel, 63 FR 67132 (1998). DEA,
however, has recognized a limited exception to this rule in cases which
commence with the issuance of an immediate suspension order because of
the collateral consequences which may attach with the issuance of such
a suspension. See William R. Lockridge, 71 FR 77791, 77797 (2006). Such
``collateral consequences'' may include the loss of title to any
controlled substances that have been seized pursuant to the immediate
suspension order, see 21 U.S.C. Sec. 824(f), harm to reputation, and
having to report the suspension on future applications to either this
Agency or a state board. See Lockridge, 71 FR at 77797.
While this case commenced with the issuance of an immediate
suspension order, I nonetheless conclude it is now
[[Page 66407]]
moot. Here, while various controlled substances were seized, the
Government subsequently provided registrant with the opportunity to
transfer the controlled substances to a registered successor in
interest. See 21 U.S.C. Sec. 824(g). Thus, to the extent the
controlled substances had any market value--which appears highly
unlikely anyway given that they were in prescription vials and not
sealed commercial containers--the Government disclaimed any interest in
them. Registrant's failure to respond to the Government's offer itself
constitutes a waiver of any claim to title to the drugs. Thus, there is
no need to issue a decision on the merits to adjudicate the issue of
title to the drugs.
To the extent the issuance of the Immediate Suspension has harmed
Registrant's reputation and may result in his having to report this
action on future applications for a DEA registration or a state
license, Registrant was provided with the opportunity to request a
hearing and challenge the basis of the Government's action. Registrant
did not, however, seek to do so. See Richard C. Quigley, 79 FR 50945,
50947 (2014) (rejecting Government's contention that ISO case was not
moot because of potential harm to physician's reputation when physician
did not request a hearing).
It is acknowledged that several federal appeals courts have held
that ``the mere possibility of adverse collateral consequences is
sufficient to preclude a finding of mootness.'' In re Surrick, 338 F.3d
224, 230 (3d Cir. 2003) (quoting Dailey v. Vought Aircraft Co., 141
F.3d 224, 228 (5th Cir. 1998)). But in those cases, which involved
sanctions imposed by courts on attorneys, the person who was sanctioned
at least cared enough to litigate. Not so here. So too, this case
stands in contrast to those cases where the Agency has ruled on the
validity of a suspension order notwithstanding that a registrant
allowed his/her registration to expire and failed to file a renewal
application. See Lockridge, 71 FR at 77797 (holding case not moot where
registrant subject to ISO did not allow registration to expire until
after receiving adverse recommended decision from ALJ); see also Nirmal
Saran & Nisha Saran, 73 FR 7827, 7835 n.29 (2008) (holding case not
moot where during proceeding, registrants' registrations expired but
registrants asserted that they intended to remain in professional
practice and had attempted to renew their registrations online but been
prevented from doing so). Accordingly, I conclude that this case is
moot. See Tin T. Win, 78 FR 52802 (2013) (holding ISO proceeding moot
where physician, who allowed her registration to expire, failed to
request a hearing and no controlled substances had been seized); Robert
Charles Ley, 76 FR 20033 (2011) (holding ISO proceeding moot where
physician eventually waived his right to a hearing and no controlled
substances had been seized).
Order
Pursuant to the authority vested in me by 21 U.S.C. Sec. 824(a),
as well as 28 CFR 0.100(b) and 0.104, I order that the Order to Show
Cause and Immediate Suspension of Registration issued to Martin L.
Korn, M.D., be, and it hereby is, dismissed. This Order is effective
immediately.
Dated: October 23, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014-26447 Filed 11-6-14; 8:45 am]
BILLING CODE 4410-09-P